Efficacy of Memantine in bipolar
- Conditions
- Bipolar disorder.Bipolar affective disorder
- Registration Number
- IRCT2013091514676N1
- Lead Sponsor
- Vice chancellor for research, Kurdistan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
This study is performed on patients between the years2013 to2014 at Qods Hospital in Sanandaj admitted with a diagnosis of bipolar1 disorder in acute mania phase.
history of bipolar disorder (manic acute phase), with or without psychotic symptoms according to DSM-IV-TR clinical interview by a psychiatrist; earn at least 20 points YMRS mania that has revealed; age 18 to 60 years old; obtaining informed consent from a parent or legal guardian of the patient; living in Sanandaj, Irann.
Exclusion criteria: Alcohol and drug dependence or abuse during the 3 months prior to admission (excluding nicotine or caffeine); psychiatric disorders on Axis II (according to DSM-IV-TR), which can interfere with the study; delirium, dementia and cognitive disorders; Schizophrenia, schizoaffective disorder, and psychotic disorders; evidence of heart disease, kidney disease, liver disease (based on medical records) that may cause difficulty in the study; pregnancy and lactation; mental retardation based on clinical assessment, the therapist; history of drug allergy or adverse drug with risperidone and lithium carbonate or Memantine; any history of seizure; Memantine use of the 3 months prior to admission.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of mania. Timepoint: Baseline and weerks 1, 2, 4, 6. Method of measurement: By Young Mania Rating Scale.
- Secondary Outcome Measures
Name Time Method Severity of extrapyramidal side effects. Timepoint: weerks 1, 2, 4, 6. Method of measurement: By Extrapyramidal Symptom Rating Scale(ESRS).